Analyst Rating Update on ZIOPHARM Oncology Inc (ZIOP)

ZIOPHARM Oncology Inc (ZIOP) : The consensus on ZIOPHARM Oncology Inc (ZIOP) based on 5 analyst recommendation on the company stock is 3, which is interpreted as a Hold recommendation. Zacks Investment Research has issued a rank of 2 which endorses a Buy on the stock. However, 1 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 3 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating. 1 analyst sees the stock overvalued at current levels and advises a Strong Sell on the stock.

ZIOPHARM Oncology Inc (ZIOP) : 2 investment research analysts covering ZIOPHARM Oncology Inc (ZIOP) have an average price target of $14 for the near short term. The highest target price given by the Brokerage Firm to the stock is $21 and the lowest target is $7 for the short term. Analysts expect the variance to be within $9.9 of the average price.

Company shares have received an average consensus rating of Hold for the current week


ZIOPHARM Oncology Inc (NASDAQ:ZIOP): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $4.86 and $4.81 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $5.10. The buying momentum continued till the end and the stock did not give up its gains. It closed at $5.09, notching a gain of 4.09% for the day. The total traded volume was 1,265,716 . The stock had closed at $4.89 on the previous day.

ZIOPHARM Oncology, Inc. is a biopharmaceutical company. The Company is engaged in the acquisition, development and commercialization of a portfolio of cancer therapies through synthetic biology. The Companys pipeline includes a number of cell-based therapeutics in both clinical and preclinical testing which are focused on hematologic and solid tumor malignancies. The Companys clinical stage product candidate, Ad-RTS-IL-12 is used with the oral activator veledimex being developed for the treatment of oncology. Ad-RTS-IL-12 in combination with veledimex uses the synthetic biology platform (gene-delivery system) to produce Interleukin-12, or IL-12, a potent, naturally occurring anti-cancer protein. The Company has completed two Phase II studies evaluating Ad-RTS-IL-12 in combination with veledimex, for the treatment of metastatic melanoma, and for the treatment of metastatic breast cancer. The Company is also developing CAR-T Cells (Cytokine products).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.